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Periodontitis is an inflammatory disease that causes osteolysis and tooth loss. It is known that the nuclear factor kappa B (NF-𝜅B)
signalling pathway plays a key role in the progression of inflammation and osteoclastogenesis in periodontitis. Parthenolide (PTL), a
sesquiterpene lactone extracted from the shoots ofTanacetum parthenium, has been shown to possess anti-inflammatory properties
in various diseases. In the study reported herein, we investigated the effects of PTL on the inflammatory and osteoclastogenic
response of human periodontal ligament-derived cells (hPDLCs) and revealed the signalling pathways in this process. Our results
showed that PTL decreased NF-𝜅B activation, I-𝜅B degradation, and ERK activation in hPDLCs. PTL significantly reduced the
expression of inflammatory (IL-1𝛽, IL-6, and TNF-𝛼) and osteoclastogenic (RANKL, OPG, and M-CSF) genes in LPS-stimulated
hPDLCs. In addition, PTL attenuated hPDLC-induced osteoclastogenic differentiation of macrophages (RAW264.7 cells), as well
as reducing gene expression of osteoclast-related markers in RAW264.7 cells in an hPDLC-macrophage coculture model. Taken
together, these results demonstrate the anti-inflammatory and antiosteoclastogenic activities of PTL in hPDLCs in vitro.These data
offer fundamental evidence supporting the potential use of PTL in periodontitis treatment.
1. Introduction
Periodontitis is a highly prevalent condition in clinic andmay
lead to the destruction of alveolar bone and loss of teeth [1].
Lipopolysaccharide (LPS), a key pathogenic component of
gram-negative bacteria, has been broadly reported to par-
ticipate in periodontitis progression by inducing host cells
to produce a wide range of proinflammatory cytokines [1].
Human periodontal ligament cells (hPDLCs) are a vital
cell type involved in periodontitis as these cells maintain
the homeostasis of periodontal tissues and regulate bone
formation and resorption [2, 3]. In response to LPS, resident
hPDLCs produce a range of inflammatory cytokines and
matrixmetalloproteinases (MMPs), including tumour necro-
sis factor-𝛼 (TNF-𝛼), interleukin-1 (IL-1), IL-6, MMP-2, and
MMP-9, which are responsible for activation of circulating
immune cells and degradation of extracellularmatrix [1, 4]. In
addition, hPDLCs secrete osteoclastogenic-related cytokines,
such as osteoprotegerin (OPG) and receptor activator of
nuclear factor kappa B ligand (RANKL), which are essential
in regulating alveolar bone destruction [5]. Furthermore, it
has been reported that the inflammation-regulating proper-
ties of hPDLCs are triggered through the nuclear factor kappa
B (NF-𝜅B) signalling pathway [6], indicating that NF-𝜅Bmay
be a potential target for improving periodontitis therapies.
Parthenolide (PTL), a sesquiterpene lactone extracted
from the shoots of Tanacetum parthenium, has been widely
used to treat headache, migraine, and arthritis due to its
anti-inflammatory properties [7]. In addition, PTL has also
been reported to ameliorate endotoxic shock and prevent
inflammation in immune glomerulonephritis [8, 9].The anti-
inflammatory properties of PTL may result from its NF-𝜅B
inhibiting ability, which has been previously demonstrated in
HeLa and macrophage cell lines [10, 11]. However, the effects
of PTL on periodontitis-related cells have yet to be reported.
Based on previous studies of PTL, we hypothesized that
PTLmay inhibit LPS-induced signalling pathways and reduce
inflammatory- and osteoclastogenic-related gene expression
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in hPDLCs. In the study reported herein, we investigated
the effects of PTL on NF-𝜅B and extracellular signal-regu-
lated kinases (ERK) signalling pathways in LPS-stimulated
hPDLCs. In addition, the effects of PTL on LPS-induced
inflammatory and osteoclastogenic-related gene expression
in hPDLCswere investigated. Furthermore, the effects of PTL
on hPDLCs-induced osteoclastogenesis inmacrophages were
determined using a Transwell coculture technique.
2. Methods
2.1. Cell Culture. hPDLCs and the murine-derived macro-
phage cell line RAW 264.7 cells were used in this study.
Human teeth samples were obtained from consenting donors
with ethical approval from the Queensland University of
Technology. hPDLCs were isolated from healthy wisdom
teeth from three different donors. The periodontal ligament
was gently removed from the middle third of the root surface
under sterile conditions. The tissue explants were then trans-
ferred to a primary culture flask and cultured in low glucose
Dulbecco’s Modified Eagle Medium (DMEM; Life Technolo-
gies, Australia) containing 10% (v/v) fetal bovine serum (FBS;
in vitro, Australia) and 1% (v/v) penicillin/streptomycin (P/S;
Life Technologies, Australia). The cells were allowed to grow
out of the explant tissue in humidified air with 5% CO
2
at
37∘C, with fresh medium provided every 3 days. hPDLCs at
passage 3 were used in the subsequent experiments.
RAW 264.7 cell cultures were maintained in DMEM
supplemented with 10% FBS and 1% (v/v) P/S at 37∘C in a
humidified CO
2
incubator. The cells were expanded through
two passages before being used in the following experiments.
2.2. Cell Proliferation. The effects of PTL (Sigma-Aldrich,
USA) on hPDLC proliferation were investigated using a 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. hPDLCs were seeded at a density of 3 ×
103 cells/well in 96-well microplates and were allowed to
adhere and spread for 12 h. The cells were then treated with
various concentrations of PTL (1, 5, 10, and 20𝜇M) for 1,
3, and 7 days, after which the cells were incubated with
MTT solution (0.5mg/mL, Sigma-Aldrich) at 37∘C for 4 h.
Dimethyl sulfoxide (DMSO; Sigma-Aldrich)was then used to
dissolve the formazan crystals.The absorbance wasmeasured
at 495 nm using SpectraMax Microplate Reader (Molecular
Devices, USA).
2.3. NF-𝜅B and ERK Signalling Pathways in hPDLCs in
Response to PTL. The effects of PTL on the expression of NF-
𝜅B, I-𝜅B, and ERK in hPDLCs were evaluated by Western
blotting. hPDLCs were pretreated with 1 𝜇M PTL for 1 h
and then stimulated with Escherichia coli LPS (1 𝜇g/mL,
Sigma-Aldrich) for 15, 30, and 60min. Whole cell lysates
were collected in a lysis buffer containing 1% Ipegal, 1%
sodium dodecyl sulphate, 50mM Tris-HCl, 150mM NaCl,
and protease inhibitor cocktail (Roche, Swiss) at indicated
time points.Theprotein concentrationwas determined by the
bicinchoninic acid (BCA; Thermo Fisher Scientific, Aus-
tralia) assay. Equal amounts of protein (10 𝜇g) were prepared
and separated using 10% sodium dodecyl sulphate poly-
acrylamide gel electrophoresis (SDS-PAGE) and were then
transferred onto nitrocellulose membranes (Pall Corpora-
tion, USA). The membranes were incubated with primary
antibodies overnight at 4∘C in Odyssey blocking buffer (LI-
COR Biosciences, USA). Primary antibodies include anti-I-
𝜅B, -NF-𝜅B, -ERK, and -p-ERK (1 : 1000) fromCell Signalling
Technology, USA, and anti-GAPDH (1 : 1000) from Abcam,
USA. The membranes were then washed twice in Tris-buf-
fered saline containing 0.05% Tween-20 and then incubated
with the corresponding fluorescent secondary antibodies
(Cell Signalling Technology, USA) for 1 h at room temper-
ature. Images were then captured and analysed using the
Odyssey Infrared Imaging system and software (LI-COR
Biosciences).
2.4. Matrix Metalloproteinase- (MMP-) 2 andMMP-9 Expres-
sion in PDLCs. Theeffects of PTL on the expression ofMMP-
2 and MMP-9 in hPDLCs were investigated at the gene and
protein level. hPDLCs were pretreated with PTL (1 and 5 𝜇M)
for 1 h and then stimulatedwithEscherichia coliLPS (1𝜇g/mL,
Sigma-Aldrich) for 1 and 3 days. Cells cultured in medium
only served as the negative control, while cells cultured with
LPS only served as the positive control. Cells were collected
and subjected to Western blotting analysis using the same
methods as described in Section 2.3. Primary antibodies
include anti-MMP-2 and MMP-9 (1 : 1000) from Abcam,
USA.
PTL-induced changes in hPDLC gene expression were
determined using quantitative reverse transcriptase poly-
merase chain reaction (qRT-PCR). Primers for the target
genes are listed in Table 1. Total RNA was collected and
extracted using TRIzol reagent (Life Technologies). First
strand cDNA was synthesized using the DyNAmo cDNA
Synthesis Kit (Thermo Fisher Scientific, USA), as per the
manufacturer’s protocol. qRT-PCR was performed using
SYBR reagent in an ABI 7500Thermal Cycler (Applied Bios-
ystems, Australia).
2.5. Anti-Inflammatory and Antiosteoclastogenic
Activity of PTL
2.5.1. Inflammatory- and Osteoclastogenic-Related Gene Ex-
pression in hPDLCs. The effects of PTL on the gene expres-
sion of inflammatory cytokines (IL-1, IL-6, and TNF-𝛼) and
osteoclastogenic-related factors (RANKL, OPG, andM-CSF)
in hPDLCs were investigated by qRT-PCR as described in
Section 2.4. Cells were also treated as described in the above
section. Primers for the target genes are listed in Table 1.
2.5.2. Coculture of hPDLCs and Macrophages. hPDLCs have
been previously reported to regulate osteoclastic differentia-
tion [2]. hPDLC-macrophage Transwell coculture technique
was therefore employed to further investigate the effects of
PTL on hPDLC-regulated macrophage-osteoclast differenti-
ation [12]. Briefly, hPDLCs were seeded into the insert of the
Transwell (Corning, USA) and treated with LPS containing
different concentrations of PTL (0, 1, and 5𝜇M) for 48 h.
Wells containing medium only were included as the control.
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Table 1: Primers used in qRT-PCR.
Gene: Homo sapiens (H) &Mus musculus (M) Primers: forward (F) & reverse (R)
IL-1 (H) F: 5
󸀠-TTACAGTGGCAATGAGGATGAC-3󸀠
R: 5󸀠-TGCTGTAGTGGTGGTCGGAGA-3󸀠
IL-6 (H) F: 5
󸀠-AGGAGACTTGCCTGGTGAAA-3󸀠
5󸀠-CAGGGGTGGTTATTGCATCT-3󸀠
TNF-𝛼 (H) F: 5
󸀠-CCTGGTATGAGCCCATCTATC-3󸀠
R: 5󸀠-GGTTGGATGTTCGTCCTCCTC-3󸀠
RANKL (H) F: 5
󸀠-AGAGCAGAGAAAGCGATGGTG-3󸀠
R: 5󸀠-GAACCAGATGGGATGTCGGT-3󸀠
OPG (H) F: 5
󸀠-CGCTCGTGTTTCTGGACATCT-3󸀠
R: 5󸀠-CACACGGTCTTCCACTTTGC-3󸀠
M-CSF (H) F: 5
󸀠-AGCATGACAAGGCCTGCGTC-3󸀠
R: 5󸀠-AAGCTGTTGTTGCAGTTCTTGC-3󸀠
MMP-2 (H) F: 5
󸀠-CCGTCGCCCATCATCAA-3󸀠
R: 5󸀠-AGATATTGCACTGCCAACTCT-3󸀠
MMP-9 (H) F: 5
󸀠-TCGTGGTTCCAACTCGGTTT-3󸀠
R: 5󸀠-GCGGCCCTCGAAGATGA-3󸀠
18s (H) F: 5
󸀠-TTCGGAACTGAGGCCATGAT-3󸀠
R: 5󸀠-CGAAC CTCCGACTTCGTTC-3󸀠
RANK (M) F: 5
󸀠-GCAGCTCAACAAGGATACGG-3󸀠
R: 5󸀠-GGTGCAGTTGGTCCAAGGTT-3󸀠
Calcitonin Receptor (M) F: 5
󸀠-CTTAGCTGCCAGAGGGTGAC-3󸀠
R: 5󸀠-TGCAACTTATAGGATCCCGCC-3󸀠
Carbonic Anhydrase II (M) F: 5
󸀠-AGCAGCGAGCAGATGTCTC-3󸀠
R: 5󸀠-TGAGCTGGACGCCAGTTG-3󸀠
MMP-9 (M) F: 5
󸀠-GGGCGTGTCTGGAGATTCG-3󸀠
R: 5󸀠-CACCTGGTTCACCTCATGGTC-3󸀠
Cathepsin K (M) F: 5
󸀠-CCAGTTTTACAGCAGAGGTGTG-3󸀠
R: 5󸀠-CTTGCTTCCCTTCTGGGTG-3󸀠
TRAP (M) F: 5
󸀠-CACTCCCACCCTGAGATTTGT-3󸀠
R: 5󸀠-CATCGTCTGCACGGTTCTG-3󸀠
𝛽-actin (M) F: 5
󸀠-CATACCCAAGAAGGAAGGCTGG-3󸀠
R: 5󸀠-GCTATGTTGCTCTAGACTTCGAGC-3󸀠
The medium was then discarded and murine macrophage
RAW264.7 cells were then seeded into the lower chamber
of the Transwell with fresh medium containing recombinant
human soluble RANK Ligand (RANKL; 10 ng/mL, Chemi-
con, Australia). The macrophage RAW264.7 cells were then
cocultured with hPDLCs for 7 days. Expression of osteo-
clastic genes (RANK, Calcitonin Receptor, Carbonic Anhy-
drase II, MMP-9, Cathepsin K, and TRAP) in RAW264.7
cells was then determined using qRT-PCR as described in
Section 2.4 and hPDLC-induced osteoclasts were identified
using tartrate-resistant acid phosphatase (TRAP) staining as
described below.
2.5.3. TRAP Staining. Following coculture with hPDLCs,
RAW264.7 cells were fixed in a mixture of citrate (6.75mM),
acetone (65%), and formalin (3.7%). TRAP staining was per-
formed using a TRAP staining assay kit (Sigma-Aldrich),
as per manufacturer’s instructions. TRAP-positive multinu-
cleated cells (MNCs) containing three or more nuclei were
regarded as osteoclasts. Images were captured using a Nikon
ECLIPSE TS100 microscope (Nikon, Australia).
2.6. Statistical Analysis. All assays were performed in tripli-
cate, with each treatment tested individually three times in
cells from three different patients. All data were converted
to the fold change of the control and one-way ANOVA with
Student-Newman-Keuls (S-N-K) test was used to analyse the
statistical difference. A 𝑃 value of <0.05 was regarded as
statistically significant.
3. Results
3.1. Effect of PTL on hPDLC Proliferation. To identify the
effects of PTL on cell proliferation, hPDLCs were treated with
different concentrations of PTL (1, 5, 10, and 20 𝜇M) for 1, 3,
and 7 days (Figure 1). As shown in Figure 1, no effects of PTL
at 1 and 5 𝜇M on hPDLC proliferation were detected com-
pared to the control (𝑃 > 0.05). However, 10 𝜇MPTL reduced
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Figure 1: Effect of PTL on hPDLC proliferation. hPDLCs were
exposed to PTL (1, 5, 10, and 20 𝜇M) for 1, 3, and 7 days. Cell
proliferation was measured using the MTT assay. The data are
expressed as the percentage of the control (containing medium
only). Error bars indicate mean ± SEM (𝑛 = 3). ∗𝑃 < 0.05 versus
the control.
hPDLC proliferation by 29.3% ± 2.4% at day 7 compared to
the control (𝑃 < 0.05). In addition, hPDLC proliferation was
40.6% ± 4.2%, 71.2% ± 2.1%, and 83.9% ± 0.8% below the
control (𝑃 < 0.05), when exposed to 20𝜇M PTL for 1, 3, and
7 days, respectively. Taken together, these data indicate that
PTL inhibits hPDLC proliferation in a dose-dependent man-
ner, notwithstanding the fact that PTL at 1 and 5 𝜇M has no
inhibitory effects on hPDLC proliferation.
3.2. Effects of PTL on Signalling Pathways in hPDLCs. The
effects of PTL on the expression of NF-𝜅B, I-𝜅B, and ERK in
hPDLCs were evaluated as they play vital roles in mediating
the inflammation process in periodontitis [6]. As shown in
Figure 2, expression of NF-𝜅B/p50 and p-ERK were signifi-
cantly increased, while I-𝜅B was decreased in hPDLCs when
exposed to LPS for 15, 30, and 60min compared to the
control (𝑃 < 0.05). However, PTL downregulated p-ERK and
NF-𝜅B/p50 expression at 30 and 60min and upregulated I-
𝜅B expression, at 15, 30, and 60min in hPDLCs compared to
LPS-treated cells (𝑃 < 0.05). In summary, these data illus-
trated that PTL reduced p-ERK and NF-𝜅B/p50 abundance,
and it also increased I-𝜅B expression in hPDLCs.
3.3. Effects of PTL on the Protein andGene Expression ofMMP-
2 andMMP-9. MMP-2 andMMP-9 have been demonstrated
to regulate proteolytic degradation in periodontitis [4]; the
effects of PTL on the expression of MMP-2 (Figure 3(a)) and
MMP-9 (Figure 3(b)) in hPDLCs were therefore investigated.
As is illustrated in Figure 3, LPS increasedMMP-2 andMMP-
9 protein abundance at day 3 as well as gene expression at
both day 1 and day 3 in hPDLCs compared to the control
(𝑃 < 0.05). However, no effect of PTL on MMP-2 protein
abundance or gene expression was observed. Indeed, MMP-9
protein expression was below the LPS group (𝑃 < 0.05) when
exposed to 1 or 5 𝜇M PTL for 3 days. In addition, 5 𝜇M PTL
significantly reducedMMP-9 gene expression at day 1 and day
3 compared to the LPS group (𝑃 < 0.05). These results indi-
cate that PTL downregulates MMP-9 protein abundance and
gene expression in hPDLCs but has no effect on the expres-
sion of MMP-2.
3.4. Effects of PTL on the Expression of Inflammatory and
Osteoclastogenic Genes. Based on the MTT assay results,
expression of inflammatory genes (IL-1, IL-6, and TNF-
𝛼; Figure 4(a)) and osteoclastogenic genes (RANKL, OPG,
and M-CSF; Figure 4(b)) in hPDLCs was determined after
exposure to PTL at 1 and 5𝜇Mfor 1 and 3 days.The expression
of all genes was upregulated compared with the control (𝑃 <
0.05) when exposed to LPS for either 1 or 3 days. However,
5 𝜇M PTL significantly reduced the expression of IL-1, IL-
6, TNF-𝛼, RANKL and M-CSF genes, and it also increased
OPG gene expression (compared to LPS group, 𝑃 < 0.05).
With the exception, 1 𝜇M PTL had no effect on IL-1 and
M-CSF expression at day 1; 1 𝜇M PTL also induced the
above changes in gene expression in hPDLCs. In summary,
these results indicate that PTL inhibits inflammation- and
osteoclastogenesis-related gene expression in hPDLCs after
stimulation with LPS.
3.5. PTL Attenuates hPDLC-Induced Osteoclastogenic Differ-
entiation in Macrophages. hPDLCs have been reported to
influence osteoclastogenic differentiation in RAW264.7 cells
[12]. TRAP staining was therefore used to identify the effects
of PTL on hPDLC-induced osteoclastogenic differentiation
in RAW264.7 cells (Figure 5) as TRAP is highly expressed
in osteoclasts. A higher percentage of MNCs (osteoclasts)
were detected in RAW264.7 cells when cocultured with LPS-
treated hPDLCs compared to the control group. However,
decreased MNCs were observed in RAW264.7 cells when
cocultured with PTL- and LPS-treated hPDLCs compared to
the hPDLCs treated with LPS alone. These results demon-
strate that PTL inhibits hPDLC-induced osteoclastogenic
differentiation in RAW264.7 cells.
3.6. Effects of PTL on the Expression of Genes in Osteoclasts.
To further identify the effects of PTL on osteoclastogenic
differentiation in RAW264.7 cells, expression of osteoclast-
related genes, including RANK, Calcitonin Receptor, Car-
bonic Anhydrase II, MMP-9, Cathepsin K, and TRAP,
was investigated following coculture with treated hPDLCs
(Figure 6). Expression of all genes listed was increased in
RAW264.7 cells when they were cocultured with LPS-treated
hPDLCs, compared to the control (𝑃 < 0.05); however, PTL-
(5 𝜇M) and LPS-treated hPDLCs significantly decreased the
expression of those genes compared to the hPDLCs treated
with LPS alone (𝑃 < 0.05). In addition, PTL- (1 𝜇M) and LPS-
treated hPDLCs downregulated RANK, Calcitonin Receptor,
MMP-9, and Cathepsin K gene expression compared to the
cells treated with LPS alone (𝑃 < 0.05). These data provide
further evidence supporting the osteoclastogenesis-inhibit-
ing ability of PTL.
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Figure 2: Effects of PTL on signalling pathways in hPDLCs. hPDLCs were pretreated with PTL 1𝜇M for 1 hour and then stimulated by LPS
for 15, 30, and 60min. Protein abundance was determined by Western blot. Error bars indicate mean ± SEM (𝑛 = 3). #𝑃 < 0.05 versus the
blank group while ∗𝑃 < 0.05 versus the LPS group.
4. Discussion
Bacteria-induced inflammation and osteolysis are the most
important pathological conditions in periodontitis [1]. Criti-
cally, current strategies to prevent or treat periodontitis are
far from satisfactory. Numerous reports have focused on
the key role of hPDLCs in periodontitis, as they produce
inflammatorymediators and induce osteoclast differentiation
in response to bacterial pathogens [2, 5]. PTL, an active con-
stituent of the plant Tanacetum parthenium, has been shown
to have potential in the treatment of inflammatory diseases
[8, 9]. We report above, for the first time, that PTL inhibits
the production of inflammatory cytokines,MMPs, and osteo-
clastogenic cytokines in LPS-stimulated hPDLCs, as well as
suppressing hPDLC-induced osteoclastogenic differentiation
of macrophages.
The transcriptional factor NF-𝜅B has been found to play
essential roles in regulating the expression of LPS-induced
inflammatory cytokines, such as IL-1, IL-6, IL-8, TNF-𝛼, and
RANKL [10, 13].These cytokines, in turn, contribute to osteo-
clast activation and bone destruction in periodontitis. Previ-
ous studies have shown that blockade of TNF-𝛼 and RANKL
by neutralizing antibodies only partially suppresses LPS-
induced osteoclastogenesis [14].Therefore, amore reasonable
approach is to inhibit theNF-𝜅Bpathwaywhich is responsible
for their production. In most cell types, NF-𝜅B is bound to
its inhibitor I-𝜅B and resides in the cytoplasm as an inactive
NF-𝜅B/I-𝜅B complex [13]. The activated form of NF-𝜅B is
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Figure 3: Effect of PTL on the expression of MMP-2 andMMP-9. (a) Expression of MMP-2; (b) expression of MMP-9. hPDLCs were treated
with PTL (1 and 5𝜇M) for 1 and 3 days and then total protein andRNAwere collected.The abundance of proteinswas detected byWestern blot.
GAPDH was included as a loading control. The intensities of the bands were measured with densitometry and first normalized to GAPDH
and then further converted to the percentage of the control (containing medium only). Error bars indicate mean ± SEM (𝑛 = 3). #𝑃 < 0.05
versus the control while ∗𝑃 < 0.05 versus the LPS group.
a heterodimer of the p65 subunit associated with either the
p50 or the p52 subunit, and then the activated NF-𝜅B
migrates into the nucleus and initiates the expression of
inflammatory genes [13]. Our results demonstrate that PTL
inhibits the NF-𝜅B signalling pathway in LPS-stimulated
hPDLCs via decreasing NF-𝜅B p50 activation and I-𝜅B
degradation.The NF-𝜅B-inhibiting ability of PTL may there-
fore support the role for its anti-inflammatory potential in
periodontitis. Other studies also found that PTL directly
binds to I-𝜅B kinase in the HeLa cell line and inhibits p65
translocation in macrophages and osteoclasts [8–11]. How-
ever, the exact target of PTL has to be confirmed in future
studies.
Besides the NF-𝜅B signalling pathway, mitogen-activated
protein kinases (MAPKs), including ERKs, c-Jun N-terminal
kinases (JNKs), and p38 MAPK also play important roles in
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Figure 4: Effect of PTL on hPDLC gene expression. (a) Expression of inflammatory genes (IL-1𝛽, IL-6, and TNF-𝛼); (b) expression of
osteoclastogenic genes (M-CSF, RANKL, and OPG). hPDLCs were treated with PTL (1 and 5 𝜇M) for 1 and 3 days and then total RNA was
collected. After RNA extraction, first strand cDNA was synthesized. The cDNA sample was then amplified using qRT-PCR. The expression
of the target gene was first normalized to 18S and then further converted to the percentage of the control (containing medium only). Error
bars indicate mean ± SEM (𝑛 = 3). #𝑃 < 0.05 versus the control while ∗𝑃 < 0.05 versus the LPS group.
mediating inflammation-related signalling pathways [15]. It
has been reported that IL-1 induced RANKL expression in
hPDLCs is mediated by the phosphorylation of ERK [16].
In addition, the ERK inhibitor but not JNK or p38 MAPK
inhibitor has been shown to attenuate force-mediated stim-
ulation of NF-𝜅B-DNA binding in hPDLCs [15], indicating
the importance of ERK signalling in periodontitis and its
correlation with NF-𝜅B. Furthermore, a previous study has
reported that PTL reduced IL-8 production by inhibiting
both ERK and NF-𝜅B pathways [17]. Our study suggests
that PTL inhibits LPS-induced phosphorylation of ERK in
hPDLCs, demonstrating the possiblemechanisms of the anti-
inflammatory effects of PTL on hPDLCs.
MMP-2 and MMP-9, also called type IV collagenases or
gelatinases, are involved in the digestion of bone collagen [4].
Indeed, MMP-9 levels in gingival crevicular fluid have been
used to identify the stage of periodontitis [4]. PTL and its
derivations have been shown to inhibit MMP-9 expression in
breast cancer cells and prevent tumour metastasis [18]. Our
study also demonstrated that PTL suppressed MMP-9 gene
expression and protein abundance, indicating the potential of
PTL in preventing matrix degradation in periodontitis. One
possible underlying mechanism might be via PTL inhibiting
theNF-𝜅B signalling pathway. It is worth noting that PTL had
no significant influence on LPS-inducedMMP-2 production.
It is known, however, that the transcriptional promoters of
MMP-2 and MMP-9 are distinct, albeit they are in fact func-
tionally related to each other [19]. There is a range of tran-
scriptional factors, including NF-𝜅B, AP-1, PEA3, Sp-1, and
𝛽-catenin/Tcf-4, which can regulate the expression of MMP
genes due to several cis-elements in the promoters of MMPs
[19]. Our results nevertheless indicate that inhibition of NF-
𝜅B signalling might be not sufficient to abrogate MMP-2
production.
The importance of inflammatory cytokines in periodon-
titis has been well documented. It has been reported that IL-1
and TNF-𝛼 antagonists inhibit the inflammatory responses
and bone destruction in experimental periodontitis [20, 21].
PTL has also been previously reported to inhibit inflamma-
tory cytokines (IL-1, IL-6, and TNF-𝛼), chemokine (IL-8),
and cyclooxygenase inmacrophages and epithelium cells [22,
23]. PTL also attenuates LPS-induced systemic inflammation
by reducing circulating IL-6 and TNF-𝛼 in animal model [24,
25]. Consistentwith previous studies, our results demonstrate
that LPS upregulates IL-1, IL-6, andTNF-𝛼 gene expression in
hPDLCs, whereas pretreatment with PTL effectively inhibits
the production of these cytokines, thus indicating the anti-
inflammatory potential of PTL in treatment of periodontitis.
Furthermore, the inhibitory effect of PTL on LPS-induced
IL-1, IL-6, and TNF-𝛼 synthesis could, at least in part,
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contribute to the downregulation of matrix degradation
and osteoclastogenesis, for all these cytokines participate in
the production of metalloproteinases and osteoclastogenic
factors of RANKL and M-CSF [26].
In periodontal tissue RANKL, M-CSF and OPG are
essential regulators of alveolar bone resorption [1, 27].
RANKL controls osteoclast differentiation and activation via
binding to its receptor (RANK) which is located on the
cell surface of osteoclast precursors [28]. OPG is a RANKL
“decoy” receptor preventing osteoclast differentiation [28].
A decreased ratio of OPG/RANKL has been reported in
periodontal tissue with periodontitis [1]. Further, the OPG/
RANKL system has been reported to play essential roles in
regulating hPDLC-induced osteoclast differentiation [1]. M-
CSF is another essential factor for osteoclast formation
through binding to the M-CSF receptor on osteoclast surface
and activation of the Akt signalling pathway [29]. In this
study, we found that PTL increased antiosteoclastogenic gene
of OPG and attenuated expression of the osteoclastogenic
genes RANKL and M-CSF in LPS-stimulated hPDLCs, indi-
cating antiosteoclastogenesis potential of PTL in periodontal
diseases. In addition, as NF-𝜅B signaling is the key regulator
of inflammation and osteoclastogenesis, the inhibitory effect
of PTL on NF-𝜅B pathway might contribute to the downreg-
ulation of inflammatory- and osteoclastogenic-related genes
in hPDLCs.
As previous studies have demonstrated, PTL could
directly inhibit osteoclastogenic differentiation. Yip et al.
applied PTL directly to cell culture of macrophages and
found that PTL inhibits osteoclastogenesis of macrophage
and osteoclastic bone resorption [10]. In contrast, our study
focuses on the effect of PTL on hPDLCs. It is well known that
hPDLCs could secret soluble cytokines that influence osteo-
clast differentiation and activity. Our previous data showed
that PTL inhibits cytokines production of hPDLCs. Subse-
quently, we aimed to clarify whether PTL-treated hPDLCs
could suppress osteoclasts differentiation of macrophages.
Therefore, a Transwell coculture technique using RAW264.7
cells and hPDLCs was employed in this study. In our cocul-
ture study, osteoclast differentiation related markers, includ-
ing RANK [28] and Calcitonin Receptor [30], were reduced
in RAW264.7 cells when they were cocultured with PTL-
treated hPDLCs. Moreover, genes regulating bone resorption
of osteoclasts (Cathepsin K, MMP-9, Carbonic Anhydrase II,
and TRAP [30, 31]) were reduced when they were cocul-
tured with PTL-treated hPDLCs. These results indicate that
PTL could possibly inhibit osteoclastogenic differentiation of
RAW264.7 cells by regulating the production of soluble fac-
tors (such as RANKL,OPG, andM-CSF) in hPDLCs. In other
words, PTL could suppress osteoclastogenic differentiation
indirectly by influencing hPDLCs. This finding offers further
evidence supporting the potential of PTL as an antiresorption
therapy in periodontitis.
Conventional treatment for periodontitis, including
mechanical scaling or disinfection therapies, is generally
successful in eliminating bacterial infection. However, it
remains a challenge to completely halt the inflammatory
process and prevent bone resorption. In this study, we found
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Figure 7: The underlying mechanisms of the effects of PTL
treatment on hPDLCs and RAW 264.7 cells.
that PTL reduced the inflammatory- and osteoclastogenic-
related gene expression in LPS-stimulated hPDLCs. These
findings provide fundamental evidence supporting further
investigation on the effect of PTL in periodontitis using
animal models. Clinically, PTL possesses great potential to
be used as complementary medicine to control inflammation
and bone resorption in periodontitis. For instance, PTL could
be incorporated into a hydrogel or periodontal dressing
paste, which can be applied to periodontal lesions following
scaling treatment or periodontal flap operation. Further
studies are needed to optimize the formulation of PTL and
to clarify its pharmacokinetic properties in preparation for
in vivo studies and clinical use.
In summary, this study has shown that PTL inhibits
the activation of NF-𝜅B and ERK signalling pathways, as
well as the expression of inflammatory and osteoclastogenic
genes in LPS-stimulated hPDLCs in vitro. Additionally, PTL
suppresses osteoclast differentiation of macrophages induced
by LPS-stimulated hPDLCs.The possible mechanisms for the
inhibitory effects of PTL on the inflammation and osteo-
clastogenesis of hPDLCs were summarised in Figure 7. Our
overall findings provide fundamental evidence supporting
the premise that PTL has the potential to be utilized as a sup-
plement medicine for the current therapeutic treatment of
periodontitis.
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